- Home
- XBIT vs CBAT Comparison
XBIT vs CBAT Comparison
Compare XBIT & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- CBAT
- Stock Information
- Founded
- XBIT 2005
- CBAT 1999
- Country
- XBIT United States
- CBAT China
- Employees
- XBIT N/A
- CBAT N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- CBAT Industrial Machinery/Components
- Sector
- XBIT Health Care
- CBAT Miscellaneous
- Exchange
- XBIT Nasdaq
- CBAT Nasdaq
- Market Cap
- XBIT 82.3M
- CBAT 90.4M
- IPO Year
- XBIT 2015
- CBAT N/A
- Fundamental
- Price
- XBIT $2.62
- CBAT $0.94
- Analyst Decision
- XBIT
- CBAT
- Analyst Count
- XBIT 0
- CBAT 0
- Target Price
- XBIT N/A
- CBAT N/A
- AVG Volume (30 Days)
- XBIT 61.7K
- CBAT 211.1K
- Earning Date
- XBIT 11-12-2025
- CBAT 11-11-2025
- Dividend Yield
- XBIT N/A
- CBAT N/A
- EPS Growth
- XBIT N/A
- CBAT N/A
- EPS
- XBIT N/A
- CBAT N/A
- Revenue
- XBIT N/A
- CBAT $145,462,366.00
- Revenue This Year
- XBIT N/A
- CBAT N/A
- Revenue Next Year
- XBIT N/A
- CBAT $60.02
- P/E Ratio
- XBIT N/A
- CBAT N/A
- Revenue Growth
- XBIT N/A
- CBAT N/A
- 52 Week Low
- XBIT $2.50
- CBAT $0.57
- 52 Week High
- XBIT $8.32
- CBAT $1.30
- Technical
- Relative Strength Index (RSI)
- XBIT 37.18
- CBAT 54.63
- Support Level
- XBIT $2.62
- CBAT $0.87
- Resistance Level
- XBIT $2.72
- CBAT $1.02
- Average True Range (ATR)
- XBIT 0.12
- CBAT 0.04
- MACD
- XBIT -0.01
- CBAT 0.01
- Stochastic Oscillator
- XBIT 2.49
- CBAT 53.25
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.